

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Stephen Barry Parker
<b>Date of last notice</b>	9 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	1. <u>Direct</u> Mr Stephen Barry Parker  2. <u>Indirect</u> Held through a UK Individual Savings Account ("ISA") Registered Holder is Barclays Bank PLC
<b>Date of change</b>	7 October 2021
<b>No. of securities held prior to change</b>	1. <u>Direct holdings</u> Mr Stephen Barry Parker 600,000 Performance Rights Class A expiring 1 April 2025 1,400,000 Performance Rights Class B expiring 1 April 2025 600,000 Performance Rights Class C expiring 30 June 2024  2. <u>Indirect holdings</u> Barclays Bank PLC 282,316 Fully Paid Ordinary Shares
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	600,000

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil – Issued on exercise of Class C Performance Rights
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li><u>Direct holding</u> Mr Stephen Barry Parker 600,000 Fully Paid Ordinary Shares 600,000 Performance Rights Class A expiring 1 April 2025 1,400,000 Performance Rights Class B expiring 1 April 2025</li> <li><u>Indirect holding</u> Barclays Bank PLC 282,316 Fully Paid Ordinary Shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Incentive Performance Rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

Rule 3.19A.2

+ See chapter 19 for defined terms.